BEDFORD, Mass., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on September 2, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $9.15, which equaled... Read More

Regenerative Solutions revenue up 41% with Integrity ™ Implant System ahead of expectations and continued strong Hyalofast ® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025 Company released topline results for Hyalofast ® clinical trial which did not meet pre-specified co-primary end points; Hyalofast demonstrated statistically significant improvements in pre-defined... Read More

Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function Hyalofast showed statistically significant improvements over microfracture in pre-defined secondary endpoints and other measures that align with prior FDA approvals for cartilage repair products Hyalofast has been used to treat... Read More

BEDFORD, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter 2025 financial results before the opening of the market on Wednesday, July 30, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be... Read More

BEDFORD, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on July 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $10.53, which equaled the... Read More

BEDFORD, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 2, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $11.45, which equaled the... Read More

BEDFORD, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on May 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 5,000 shares of common stock at a per share exercise price of $14.46, which equaled... Read More

First Quarter 2025 Commercial Channel revenue up 18% Integrity ™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global... Read More

BEDFORD, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that management will participate in the Sidoti Virtual Investor Conference on Wednesday, May 21, 2025. Anika will host a virtual presentation with Q&A starting at 1:00pm ET. Webcast of... Read More

BEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2025 financial results before the opening of the market on Friday, May 9, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by... Read More

BEDFORD, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the Osteoarthritis (“OA”) Pain Management and Regenerative Solutions space focused on early intervention orthopedics, today announced that on April 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 3,800 shares of common stock at a per share exercise price of $15.03, which... Read More

Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant System drive Commercial Channel growth and 2024 results Key Regulatory and Clinical milestones achieved for Hyalofast ® , Cingal ® , and Integrity Strategic Sale of Parcus Medical complete; resources refocused on programs positioned to... Read More

BEDFORD, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the Osteoarthritis Pain Management and Regenerative Solutions space focused on early intervention orthopedics, today announced the completion of the previously announced planned divestiture of its Parcus Medical business. Management Commentary “The sale of Parcus marks a critical step forward as we achieve the goals... Read More

BEDFORD, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2024 financial results after the close of the market on Wednesday, March 12, 2025 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business... Read More

BEDFORD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego on Monday, March 10, 2025 at 2:30pm PT / 5:30pm ET. Management will also participate in one-on-one investor... Read More

BEDFORD, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET. Management will also participate in one-on-one... Read More

BEDFORD, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that senior management will participate in the following upcoming conferences. 36th Annual Piper Sandler Healthcare Conference in New York, NY on December 3 rd . Dr. Cheryl Blanchard, President and CEO of Anika and Steve Griffin, Executive Vice... Read More

WEST BRIDGEWATER, Mass. , Oct. 31, 2024 /PRNewswire/ -- Executive management from Primo Medical Group along with others, combined to acquire Arthrosurface, Inc., a leading provider of joint restoration and preservation solutions for active patients, from Anika Therapeutics (NASDAQ: ANIK). Two former Arthrosurface leaders joined the Primo Medical Group executives in this strategic acquisition which ensures that... Read More

BEDFORD, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced the divestiture of its Arthrosurface business and the intention to divest of the Parcus Medical business. These decisions are the result of the Company’s ongoing company-wide strategic review. Management Commentary “The goal of our previously... Read More

Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwinds Strategy to focus on market leading OA Pain Management and high-growth Regenerative Solutions Company to categorize revenue into OEM Channel and Commercial Channel; Commercial Channel remains on track to achieve ~17% CAGR... Read More

BEDFORD, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2024 financial results before the opening of the market on Thursday, October 31, 2024, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be... Read More

BEDFORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on October 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 6,350 shares of common stock at a per share exercise price of $24.27, which equaled the closing price of common stock on the Nasdaq Global Select... Read More

BEDFORD, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on September 3, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $25.15, which equaled the closing price of common stock on the Nasdaq Global... Read More

BEDFORD, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on August 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 8,850 shares of common stock at a per share exercise price of $26.29, which equaled the closing price of common stock on the Nasdaq Global Select... Read More

Expanded Regenerative Solutions portfolio with full market release of the Integrity™ Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating significant market demand Delivered revenue in line with expectations with 15% adjusted EBITDA margins; Strong first half 2024 international OA Pain Management revenue growth of 17% Enhanced capital allocation strategy with new $40... Read More

BEDFORD, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the Sidoti Virtual Investor Conference on Thursday, August 15, 2024. Anika will host a virtual presentation with Q&A starting at 11:30am ET. Webcast of the presentation and Q&A will be available in the Investor... Read More

BEDFORD, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2024 financial results after the close of the market on Thursday, August 8, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business... Read More

BEDFORD, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on July 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $25.85, which equaled the closing price of common stock on the Nasdaq Global Select... Read More

Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika’s proprietary hyaluronic acid (HA) regenerative portfolio Over 300 surgeries completed during the limited market release, highlighting the growing interest and commercial demand across a wide range of tendon repairs BEDFORD, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a... Read More

BEDFORD, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on June 3, 2024, Anika granted: (i) non-statutory stock options (“Options”) covering 96,525 shares of common stock at a per share exercise price of $29.35, which equaled 110% of the closing price of common stock on the Nasdaq Global Select... Read More

Appoints Joseph Capper and William Jellison to Board of Directors Announces New $40 Million Share Repurchase Program BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc . (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a cooperation agreement with Caligan Partners LP (“Caligan”). As part of the agreement, Joseph Capper, CEO... Read More

BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has appointed Steve Griffin as the Company’s Executive Vice President, Chief Financial Officer (“CFO”) and Treasurer, effective June 3, 2024. He succeeds Michael Levitz, who has decided to step down as CFO after almost four years with the... Read More

Revenue up 7% on growing demand and favorable order timing; On-track for 2024 revenue guidance Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30 million, up over 75% at the midpoint BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for... Read More

BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on May 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 3,800 shares of common stock at a per share exercise price of $26.49, which equaled the closing price of common stock on the Nasdaq Global Select... Read More

BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2024 financial results after the close of the market on Wednesday, May 8, 2024 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business... Read More

BEDFORD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024. Anika will host a virtual presentation with Q&A starting at 2:15pm ET. Webcast of the presentation and Q&A will be available in the... Read More

Revenue growth and adjusted EBITDA 1 exceeded expectations in the fourth quarter and full year OA Pain Management achieved record annual revenues of $102 million, up 11% in 2023 Announces cost reduction initiatives providing annualized savings of approximately $10 million Anika positioned to generate adjusted EBITDA 1 of $25 to $30 million in 2024, up over 75% at the midpoint, representing an adjusted EBITDA 1 margin of at... Read More

BEDFORD, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on March 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $25.14, which equaled the closing price of common stock on the Nasdaq Global Select... Read More

BEDFORD, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its fourth quarter and year-end 2023 financial results after the close of the market on Wednesday, March 13, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results... Read More

Announcing the limited market release of X-Twist™ Fixation System with biocomposite suture anchor for rotator cuff and other soft tissue repair at AAOS Focusing on its full Regenerative, Sports Medicine and Arthrosurface Joint Solutions portfolio addressing the over $2.0 billion U.S. rotator cuff market 1 BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation... Read More

Integrity marks Anika’s entrance into the fast-growing $150 million+ 2 U.S. rotator cuff augmentation market and expansion of its proprietary hyaluronic acid (HA) regenerative portfolio BEDFORD, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that the first surgeries using the Integrity Implant... Read More

BEDFORD, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice President, Chief Financial Officer and Treasurer, will be participating at the following investor conferences: The Stephens Annual Investment... Read More

Revenue Growth Exceeded Expectations in the Third Quarter and Year-To-Date, with Joint Preservation and Restoration up 14% and 10% and OA Pain Management up 2% and 11%, Respectively RevoMotion™ Reverse Shoulder Arthroplasty System Fully Launched at OSET Annual Meeting with Positive Surgeon Feedback Integrity™ Implant System, a Regenerative Hyaluronic Acid (HA)-Based Patch System for Augmentation of Rotator Cuff Repairs, and... Read More

BEDFORD, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2023 financial results after the close of the market on Thursday, November 2, 2023 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business... Read More

RevoMotion Reverse Shoulder Arthroplasty System significantly expands Anika’s shoulder arthroplasty portfolio and provides a bone conserving and innovative solution in the $1 billion 1 U.S. reverse shoulder market RevoMotion adds to a growing, highly differentiated portfolio to treat the full continuum of rotator cuff disease including our recently launched X-Twist™ Fixation System and newly cleared Integrity™ regenerative... Read More

BEDFORD, Mass., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on September 5, 2023, Anika granted restricted stock units ( “RSUs”) covering 10,000 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, was... Read More

BEDFORD, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the Sidoti Small Cap Virtual Investor Conference on Thursday, September 21, 2023. Anika will host a virtual presentation with Q&A starting at 10:45am ET. Webcast of the presentation and Q&A will be available in... Read More

Complete Integrity Implant System is now fully cleared; targeting launch in Q1-2024 Integrity is highly differentiated by its knitted structure, resulting in higher strength and greater regenerative capacity compared to first generation bovine collagen patches 1 Integrity marks Anika’s expansion of its proprietary regenerative portfolio and entrance into the over $150 million 2 U.S. rotator cuff augmentation market BEDFORD,... Read More

Double Digit Q2 Revenue Growth Driven by Strong OA Pain Management Growth of 22%; Raising Low-End of Full-Year Guidance Range on Positive Year-to-Date Performance Hyalofast®, Single-Stage, Off-the-Shelf, Resorbable Hyaluronic Acid Scaffold for Cartilage Repair, Pivotal Phase III Trial Fully Enrolled; Modular PMA Submission on Track to Commence in 2024 with Final PMA Module Filing Planned in 2025 Successful RevoMotion™... Read More

BEDFORD, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2023 financial results after the close of the market on Tuesday, August 8, 2023 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business... Read More

Anika’s new X-Twist™ Fixation System, combined with its ACE Award-Winning Tactoset ® for hardware augmentation and autologous bone morrow aspirate, provide time-saving regenerative solutions for Sports Medicine surgeons Clinical outcomes of rotator cuff repair utilizing Tactoset for suture anchor augmentation will be featured during a Keystone Product Theater presentation BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE) --... Read More

Hyalofast – a single-stage, off-the-shelf, resorbable, hyaluronic acid scaffold for cartilage repair – is marketed in over 35 countries outside the U.S. where it has been clinically demonstrated to be safe and effective Hyalofast has been designated as a breakthrough device by FDA, allowing prioritized interaction and review; Anika to begin filing modular PMA in 2024 with final module filing expected in 2025 Hyalofast... Read More

BEDFORD, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its first quarter ended March 31, 2023. First Quarter 2023 Financial Summary Revenue in the first quarter of 2023 was $37.9 million, up 3% compared with $36.7 million in the first quarter of 2022. Osteoarthritis (OA) Pain... Read More

BEDFORD, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2023 financial results after the close of the market on Tuesday, May 9, 2023 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business... Read More

Gary Fischetti Joins Anika Board Announces Share Repurchase Program Forms Capital Allocation Committee BEDFORD, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a cooperation agreement with Caligan Partners LP (“Caligan”). As part of the agreement, the... Read More

BEDFORD, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the 22nd Annual Needham Virtual Healthcare Conference on Thursday, April 20, 2023. Anika will host a virtual presentation with Q&A starting at 12:45pm ET. Webcast of the presentation and Q&A will be available in... Read More

Tactoset cleared by the FDA to be combined with autologous bone marrow aspirate, a core element for regenerative healing Anika reaches agreement to distribute the Marrow Cellution™ Bone Marrow Aspiration Needle in the U.S. and commences launch Launches enhanced Tactoset cannulas, which improve targeting and ease of use in a variety of foot and ankle procedures BEDFORD, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Anika... Read More

BEDFORD, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global joint preservation company in early intervention orthopedics, today announced that it has filed its preliminary proxy materials with the Securities and Exchange Commission (“SEC”) in connection with its upcoming 2023 Annual Meeting of Stockholders (the “Annual Meeting”). The meeting date has not yet... Read More

BEDFORD, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the Sidoti Small Cap Virtual Investor Conference on Wednesday, March 22, 2023. Anika will host a virtual presentation with Q&A starting at 9:15am ET. Webcast of the presentation and Q&A will be available in the... Read More

Recently Commenced Full Market Release of X-Twist™ Fixation System, a Cornerstone Product in Anika’s Sports Medicine Portfolio RevoMotion™ Reverse Shoulder Arthroplasty System Now in Limited Market Release in U.S. OVOMotion ® with Inlay Glenoid Total Shoulder Arthroplasty (TSA) System and Tactoset ® Injectable Bone Substitute Featured at 2023 AAOS BEDFORD, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc.... Read More

Delivered Fourth Quarter Revenue Growth of 11% and Full Year 2022 Revenue Growth of 6% Completed First Surgeries and Initiated Limited Market Release of New RevoMotion™ Reverse Shoulder Arthroplasty System Commenced Full Market Release of X-Twist™ Fixation System in Sports Medicine Hyalofast ® , Anika’s Off-the-Shelf Single-Stage Cartilage Repair Product, Designated as a Breakthrough Device by FDA; Pivotal Phase III Clinical... Read More

BEDFORD, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate at the Canaccord Genuity Musculoskeletal Conference in Las Vegas, NV on Tuesday, March 7, 2023 at 3:00 p.m. PT (6:00 p.m. ET). A live audio webcast will be available in the Investor Relations section of Anika’s... Read More

BEDFORD, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its fourth quarter and year-end 2022 financial results after the close of the market on Monday, March 6, 2023 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and... Read More

BEDFORD, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today issued the following statement in response to the letter by Caligan Partners LP: Over the last six months, members of Anika’s Board of Directors and management have met with Caligan Partners eight times to better understand its views and discuss Anika’s... Read More

Believes Current Board's Strategic Missteps and Poor Capital Allocation Has Led to Significant Underperformance Offers Three Actions for Significant Change, Including Strategic Review NEW YORK , Feb. 21, 2023 /PRNewswire/ -- Caligan Partners LP ("Caligan"), one of the largest shareholders of Anika Therapeutics, Inc. (NASDAQ: ANIK) ("Anika" or the "Company"), today issued an open letter to the board of directors of Anika in... Read More

RevoMotion significantly expands Anika’s shoulder arthroplasty portfolio and provides a new solution in the over $800 million U.S. reverse shoulder market RevoMotion offers the industry’s smallest diameter threaded glenoid baseplate which preserves bone and enhances intraoperative flexibility The system’s two streamlined instrument trays are designed to drive efficiencies, reduce OR complexity, and simplify the procedure in... Read More